Therapeutic Potential of PPARγ Activation in Stroke

Raghu Vemuganti

Department of Neurological Surgery and the Neuroscience Training Program, University of Wisconsin-Madison, Madison, WI 53792, USA

Correspondence should be addressed to Raghu Vemuganti, vemugant@neurosurg.wisc.edu

Received 8 January 2008; Accepted 27 March 2008

Recommended by Paul Drew

Stroke (focal cerebral ischemia) is a leading cause of death and disability among adult population. Many pathological events including inflammation and oxidative stress during the acute period contributes to the secondary neuronal death leading the neurological dysfunction after stroke. Transcriptional regulation of genes that promote these pathophysiological mechanisms can be an effective strategy to minimize the poststroke neuronal death. Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors known to be upstream to many inflammatory and antioxidant genes. The goal of this review is to discuss the therapeutic potential and putative mechanisms of neuroprotection following PPAR activation after stroke.

Copyright © 2008 Raghu Vemuganti. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR)

PPAR and retinoid X receptor (RXR) are ligand-activated transcription factors of the nuclear hormone receptor superfamily [1, 2]. PPAR exists as 3 isoforms (α, γ, and δ/β) with distinct natural agonists for each isoform. RXR also exists as 3 isoforms (α, β, and γ), but all 3 can be activated by common ligands [3]. Both RXR and PPAR are composed of a ligand binding domain (LBD) and a DNA binding domain (DBD) [4]. When their respective ligands bind to PPAR and RXR, they form a heterodimeric complex which recruits other coactivators including PPAR coactivator-1 and -2, PPAR-binding protein, PPAR-interacting protein, CREB-binding protein and steroid receptor coactivator-1. This complex binds to the promoter regions of specific genes that contain a regulatory element known as the peroxisome proliferator response element (PPRE; AGGTCA-AGGTCA repeats) which either activates or transrepresses the target genes [1, 5]. Binding of a specific agonist to PPAR is a prerequisite for coactivator binding. In the absence of a ligand, the PPARγ:RXR complex can recruit corepressor complexes and bind to PPRE, suppressing the transcription of target genes [6]. Thus PPARs can control the gene expression positively as well as negatively.

2. FUNCTIONAL SIGNIFICANCE OF PPARs

In the mammalian body, PPARs control glucose and lipid metabolism, cell proliferation and differentiation [1, 7]. In particular, the PPARγ isoform behaves as a “molecular sensor,” binding a wide range of molecules involved in metabolism, and has been studied extensively in diabetes and obesity due to its role in regulating glucose metabolism [8, 9]. A class of synthetic, insulin-sensitizing compounds called thiazolidinediones (TZDs) have emerged as potent, exogenous agonists of PPARγ and are being prescribed for type-2 diabetes [1, 10]. PPARγ shows a highly restricted pattern of expression. It is present at a high amount in adipose tissue where it regulates adipocyte differentiation and lipid metabolism [5]. Its expression is also very high in cells of the immune system such as monocytes/macrophages, B and T cells [11]. In the normal adult brain, PPARγ shows a relatively low level of expression primarily limited to the granule cells of the hippocampal dentate gyrus [11]. Some PPARγ expression is also present in the caudate putamen and globus pallidus of the basal ganglia, thalamus, and the piriform cortex [2]. Recent studies indicated that microglia and astrocytes, the cell types that play a significant role in the inflammatory responses of the CNS show high expression levels of PPARγ [12]. More recently, several TZDs including...
the United States Food and Drug Administration (FDA) approved rosiglitazone and pioglitazone were shown to control inflammation in peripheral organs as well as CNS [13, 14].

3. PPAR LIGANDS

The endogenous agonists of PPARα include eicosanoids-like leukotriene B₄ and 8(S)-hydroxy-eicosatetraenoic acid [15], Whereas 15-deoxy-delta-12,14-prostaglandin-J₂ (15dPGJ₂), and several oxidized metabolites of hydroxyl-eicosatetraenoic acid and hydroxyl-eicosadecenoic acid are the natural ligands for PPARγ [16]. Many prostanoids are the natural ligands for PPARδ/β [17]. The 3 RXR isoforms use common ligands that include 9-cis retinoic acid, docosahexaenoic acid, and phytanic acid [3].

4. PROMOTERS OF STROKE-INDUCED BRAIN DAMAGE

Following stroke, while the ischemic core undergoes irreversible damage, the penumbra (tissue surrounding the core) can potentially be rescued with timely therapeutic intervention [18]. Typically, the penumbra is much larger in volume than the core to start with, but as the cell death progresses with time, the infarct grows in size engulfing penumbra [19]. The secondary neuronal death that eventually precipitates the long-term neurological dysfunction after stroke is caused by many synergistic pathophysiological mechanisms involving various cell types. In particular, massive inflammation that starts immediately and continues for days after focal ischemia is a major promoter of ischemic neuronal death [20]. In core of injury, anoxic depolarization promotes calcium and potassium release leading to neurotransmitter glutamate release. This follows with a wave of spreading depression which promotes further glutamate release in penumbra. Increased extracellular glutamate promotes excitotoxic secondary neuronal death in core as well as penumbra. Immediately after stroke, due to lack of oxygen and glucose, the ionic gradients across cell membranes collapse leading to water influx and edema in CNS. In addition, mitochondrial failure leads to endoplasmic reticulum (ER) stress and oxidative stress. This is followed by the increased expression of inflammatory genes and infiltration of leukocytes into brain parenchyma. All these pathophysiological events are thought to synergistically promote the postischemic neuronal death [21].

5. INFLAMMATION AFTER STROKE

In a normal brain, the blood-brain barrier (BBB) controls the infiltration of white blood cells into brain parenchyma. However, following ischemia induction of the adhesion molecules like intercellular adhesion molecule-1 (ICAM1), E-selectin, and P-selecton the endothelial cells promotes leukocyte adherence and extravasation [20]. The infiltrated macrophages and neutrophils activate resident microglia and astrocytes [22]. Following stroke, leukocytes as well as neurons, astrocytes, microglia, and oligodendrocytes generate proinflammatory mediators including cytokines like interleukin (IL)-6 and IL-1β, chemokines like macrophage inflammatory protein-1α and monocyte chemoattractant protein-1 (MCP1), prostaglandins and free radicals which exacerbate postischemic secondary neuronal death [23, 24].

6. ROLE OF TRANSCRIPTION FACTORS IN POSTISCHEMIC INFLAMMATION

Transcription factors play a central role in modulating inflammation by controlling the expression of cytokines, chemokines, and other inflammatory genes. Ischemia is a known stimulator of many transcription factors including hypoxia inducible factor-1 (HIF1), signal transducer and activator of transcription-3 (STAT3), early growth response-1 (Egr1), nuclear factor (erythroid-derived 2)-like 2 (Nrf2), interferon regulatory factor-1 (IRF1), activating transcription factor-3 (ATF3), cAMP response element binding protein (CREB), cAMP response element modulator (CREM), and nuclear factor-kappa B (NF-kB) that are known to be significantly modulate the postischemic inflammatory gene expression [25–28]. While the transcription factors like STAT3, IRF1, C/EBPβ, NF-kB, ATF3, and EGR1 promote neuronal damage by inducing inflammatory genes [26–31], transcription factors like HIF1, Nrf2, PPARα, PPARγ, and CREB are thought to be beneficial as they curtail the expression of genes that promote either inflammation or oxidative stress [32–36]. Drugs that target transcription factors could be effective as they act upstream to gene expression, thus curtailing the inflammation and other destructive pathways.

7. ANTI-INFLAMMATORY EFFECTS OF PPARγ ACTIVATION IN THE PERIPHERAL ORGANS

Many recent studies demonstrated that PPARγ agonists exert significant protection in various animal models of neurological and cardiovascular disorders [37–40]. Activated macrophages release proinflammatory cytokines such as tumor necrosis factor-α (TNFα) and IL6 and free radicals such as nitric oxide (NO) and superoxide. PPARγ activation by its agonists was shown to inhibit the expression of inducible NO synthase (iNOS) and inflammatory cytokine production in macrophages and endothelial cells [5, 41, 42]. PPARγ agonists were also shown to reduce ROS formation in coronary artery endothelial cells and cardiac fibroblasts [43, 44]. Pioglitazone was shown to curtail ICAM1 and MCP1 expression leading to decreased macrophage infiltration after cardiac ischemia leading to curtailed myocardial damage in rats [45]. PPARγ natural ligand 15dPGJ2 was shown to prevent the expression of IL6, IL1β, and TNFα in phorbol 12-myristate 13-acetate-stimulated monocytes [42]. The systemic inflammation in joints of rheumatoid arthritis patients and in the pancreas of diabetics was also shown to be minimized by treatment of PPARγ agonists [8, 46–48]. Another agonist of PPARγ, rosiglitazone treatment was shown to limit neutrophil infiltration, nitrotyrosine formation and lipid peroxidation following experimental pancreatitis in mice [49]. Rosiglitazone was also shown...
8. PPARγ ACTIVATION AND STROKE

Massive inflammation is a known precipitator of stroke-induced brain damage [20, 21, 57]. Many anti-inflammatory compounds including minocycline, curcumin, caffeic acid phenyl ester and Brazilein can limit cerebral inflammation, and thus ischemic neuronal death [58–61]. As brain damage following focal ischemia is known to be mediated by many synergistic mechanisms including edema, ionic imbalance, apoptosis, oxidative stress, and ER stress, combination of drugs that prevent some if not all these pathophysiological changes might be needed to efficiently control ischemic neuronal death.

Consistent with the known benefits of PPARγ activation in conditions of inflammation, several animal studies have demonstrated the therapeutic potential of TZDs in improving postischemic functional outcome. As 2 TZDs rosiglitazone and pioglitazone are currently approved by FDA for type-2 diabetes treatment and as the incidence of stroke and diabetes treatment increases post-ischemic functional outcome. As 2 TZDs rosiglitazone and pioglitazone are currently approved by FDA for type-2 diabetes treatment and as the incidence of stroke and diabetes treatment increases post-ischemic functional outcome. As 2 TZDs rosiglitazone and pioglitazone are currently approved by FDA for type-2 diabetes treatment and as the incidence of stroke and diabetes treatment increases post-ischemic functional outcome. As 2 TZDs rosiglitazone and pioglitazone are currently approved by FDA for type-2 diabetes treatment and as the incidence of stroke and diabetes treatment increases, several animal studies have demonstrated the therapeutic potential of TZDs in improving postischemic functional outcome. As 2 TZDs rosiglitazone and pioglitazone are currently approved by FDA for type-2 diabetes treatment and as the incidence of stroke and diabetes treatment increases, several animal studies have demonstrated the therapeutic potential of TZDs in improving postischemic functional outcome. As 2 TZDs rosiglitazone and pioglitazone are currently approved by FDA for type-2 diabetes treatment and as the incidence of stroke and diabetes treatment increases, several animal studies have demonstrated the therapeutic potential of TZDs in improving postischemic functional outcome. As 2 TZDs rosiglitazone and pioglitazone are currently approved by FDA for type-2 diabetes treatment and as the incidence of stroke and diabetes treatment increases, several animal studies have demonstrated the therapeutic potential of TZDs in improving postischemic functional outcome. As 2 TZDs rosiglitazone and pioglitazone are currently approved by FDA for type-2 diabetes treatment and as the incidence of stroke and diabetes treatment increases, several animal studies have demonstrated the therapeutic potential of TZDs in improving postischemic functional outcome. As 2 TZDs rosiglitazone and pioglitazone are currently approved by FDA for type-2 diabetes treatment and as the incidence of stroke and diabetes treatment increases, several animal studies have demonstrated the therapeutic potential of TZDs in improving postischemic functional outcome.

9. PPAR ACTS TOGETHER WITH OTHER TRANSCRIPTION FACTORS

The transrepression of inflammatory genes by PPAR acts in cooperation with many other transcription factors including NF-κB, AP-1, Egr1, and c/EBPβ, and by inhibiting the ubiquitylation/degradation of corepressor proteins via sumoylation [72]. Vascular inflammation was shown to be controlled by the interaction of PPARγ and c/EBPβ by negatively regulating the expression of inflammatory genes like IL-6, IL1β, and TNFa [73]. This is made possible by the presence of tandem repeats of c/EBPβ motif in the PPARγ promoter region enabling transactivation of PPARγ gene. The PPAR:RXR heterodimer complex also competes with the coactivator complexes as well as interacts directly with other transcription factors to regulate their function. In addition, TZDs can have PPARγ-independent actions that include mitochondrial dysfunction-related, stress-response, increased astrocyte, glucose uptake and lactate production, and modulation of the mitochondrial protein MitoNeet [74, 75].

10. EFFICACY OF PPARγ AGONISTS AFTER FOCAL ISCHEMIA

Of the two FDA-approved TZDs, pioglitazone is known to cross BBB more efficiently than rosiglitazone, but the affinity of pioglitazone to PPARγ is 10 times lower (Kd of ~400 nM) than rosiglitazone (Kd of ~40 nM) [1, 76]. In addition to stimulating PPARγ, pioglitazone also functions as a partial agonist of PPARα, whereas rosiglitazone functions as a pure PPARγ agonist [13]. To make things complicated, recent studies demonstrated that to induce the same degree of neuroprotection following focal ischemia or SCI, comparable doses of pioglitazone and rosiglitazone are needed [32, 77].

11. NONINFLAMMATION-RELATED NEUROPROTECTIVE ACTIONS OF TZDs

Although preventing inflammation seems to be the major neuroprotective mechanism of PPAR agonists after stroke,
both PPARγ and PPARα agonists were shown to induce other beneficial effects like reducing oxidative stress, increasing endothelial relaxation, and preventing apoptosis in the postischemic brain [63, 78, 79]. When oxidative stress was induced in immortalized mouse hippocampal cells by exposing to glutamate or hydrogen peroxide, PPARγ agonists protected the cells from death [39]. Transient focal ischemia is known to promote reactive oxygen species (ROS) production and reduce glutathione levels (which scavenge ROS) simultaneously [80]. This leads to enormous oxidative stress and neuronal death. The cytosolic antioxidant enzyme, endothelial copper/zinc-superoxide dismutase (Cu/Zn-SOD) is known to decrease oxygen-free radicals to mitigate eNOS inactivation [81]. Catalase, the other major antioxidant enzyme which is very active in peroxisomes of both neurons and glial cells [82, 83] protects cells by quickly degrading hydrogen peroxide. Neurons are extremely labile to oxidative damage and cellular stress is a known inducer of both Cu/Zn-SOD and catalase expression to counter the oxidative stress and to protect neurons following focal ischemia. As the promoters of SOD and catalase genes contain PPRE, they are directly upregulated when PPARγ is activated [81, 84].

Recent studies from our laboratory showed that in normotensive and hypertensive rodents subjected to transient focal ischemia, rosiglitazone treatment significantly increases Cu/Zn-SOD and catalase activity in the peri-infarct region which might be responsible for the observed neuroprotection [32]. In addition, rosiglitazone also decreased COX-2 and iNOS levels (indicating reduced production of ROS and NO) in peri-infarct neurons [34]. It was also reported that both pioglitazone and rosiglitazone significantly prevent glutathione depletion following focal ischemia in adult rats [80].

As ROS promotes apoptosis and TZDs minimize ROS formation, PPARγ activation was thought to prevent post-ischemic apoptotic neuronal death [85, 86]. A recent study showed that rosiglitazone treatment decreases caspase-3 levels leading to reduced apoptotic cell death following focal ischemia [87]. This seems to be a direct PPARγ downstream effect as pretreating animals with the PPARγ antagonist GW9662 prevented the antiapoptotic actions of rosiglitazone [87]. Pioglitazone treatment was also shown to promote the expression of antiapoptotic gene Bcl2 while simultaneously preventing the expression of proapoptotic gene Bax in the peri-infarct regions of brain following focal ischemia [13, 88].

12. PPARγ AGONIST-INDUCED NEUROPROTECTION IN HUMAN STROKE SUBJECTS

A recent clinical trial, named the Prospective Pioglitazone Clinical Trialin Macrovascular events (proactive) started evaluating if pioglitazone treatment can prevent the macrovascular events in type-2 diabetes [89, 90]. This extensive study evaluated 5, 238 patients in 19 countries. In particular, one prespecified subgroup analysis evaluated the effect of pioglitazone in patients with (n = 984) or without (n = 2867) a history of stroke and observed a 16% relative risk reduction in the pioglitazone group compared to placebo group [91]. In addition, within the group of patients with a previous stroke, pioglitazone therapy decreased the risk of recurrent stroke by 47% compared to placebo over 3 years. But pioglitazone had no effect on decreasing first strokes over this period. While this shows an encouraging trend for stroke patients, serious heart failure was observed to be increased significantly in the pioglitazone group compared to placebo group. The complete details and results of the proactive trial can be viewed at the website http://www.proactive-results.com/index.htm. Yki-Järvinen [92] commented critically on this trial that pioglitazone group showed increased edema and increased incidence of pneumonia. Furthermore, the weight gain was 4 kg greater in the pioglitazone over placebo group which is undesirable. A recent study also showed that pioglitazone or rosiglitazone therapy significantly enhanced the functional recovery in a group of 30 type-2 diabetes patients admitted in the hospital for acute stroke rehabilitation [93].

13. BENEFICIAL EFFECT OF PPARγ ACTIVATION IN OTHER CNS INJURIES

PPARγ activation by TZDs was shown to prevent inflammation and neuronal death in several in vitro and in vivo models of CNS diseases [40, 94–97]. In patients suffering with Alzheimer disease, PPARγ activation was shown to prevent TNFα and iNOS expression in macrophages, thus limiting the inflammation and cognitive impairment [40, 98]. TZDs were known to significantly reduce the dopaminergic neuronal loss leading to improved neurological status in Parkinson’s disease [99]. Using the rodent model of multiple sclerosis (experimental autoimmune encephalomyelitis), PPARγ agonist treatment was shown to suppress activation of T-cells, microglia, and macrophages thus decreasing proinflammatory factor formation leading to improved neurological outcome [94, 96, 100]. Pioglitazone oral treatment was reported to decrease the microglial activation, motor neuron loss, and muscular atrophy in transgenic mice over-expressing SOD1-G93A (an animal model of Amyotrophic lateral sclerosis) with pioglitazone [101, 102]. These mice also showed increased anti-inflammatory gene expression upon treatment with pioglitazone [101]. More recently, two studies showed the beneficial effects of treating rodents with PPARγ agonists following spinal cord injury (SCI) [77, 103]. Our laboratory demonstrated that both rosiglitazone and pioglitazone decreases inflammatory cell activation and inflammatory gene expression leading to smaller lesion size, better motor recovery, and less neuropathic pain after SCI in rats [77]. Importantly, we showed that pretreating rats with the PPARγ antagonist GW9662 prevents many beneficial effects of TZDs following SCI indicating a direct mediation of PPARγ in promoting post-SCI neuronal recovery [77].

14. PPARγ-INDEPENDENT NEUROPROTECTIVE ACTIONS OF PPARγ AGONISTS

While the anti-inflammatory and neuroprotective actions of PPARγ agonists are expected to be mediated via PPARγ
stimulation, some studies suggested that PPARγ agonists also induce many beneficial effects via PPARγ-independent mechanisms as well. 15dPGJ2 was shown to prevent astroglial and microglial activation by bacterial endotoxins without involving PPARγ [12]. The anti-inflammatory action of 15dPGJ2 was shown to be mediated by binding to and inactivating inhibitor of kappa B (IKB) kinase and by alkylating the p50/p65 dimers and thus preventing the activation of NF-kB without involving PPARγ [52, 53]. Following focal ischemia, the proinflammatory actions of the cytokine IL6 are known to be mediated by the activation of IL6 receptor-associated Janus kinases (JAKs) and their downstream STAT family of transcription factors [25]. Suppressor of cytokine signalling (SOCS) proteins act as negative feedback regulators and inhibit JAK and STAT phosphorylation, thus preventing the upregulation and binding of cytokines to their receptors after an acute CNS insult [32, 104]. Recent studies from our group and others demonstrated that rosiglitazone and 15dPGJ2 induce SOCS3 expression and prevent JAK2 and STAT3 phosphorylation [32, 105]. Thus the neuroprotective actions of PPARγ agonists might also be mediated by direct actions on JAK-STAT-SOCS pathway. Our recent studies also showed that pioglitazone treatment after SCI induces the heat shock protein (HSP)-27, HSP70, and HSP32 (hemeoxygenase-1) which induce neuroprotection [104].

15. ACTIVATION OF OTHER PPAR ISOFORMS ALSO INDUCES NEUROPROTECTION

In addition to PPARγ, PPARα, and PPARβ/δ, activation was also shown to significantly prevent inflammation and induce protection after injury to CNS as well as peripheral organs. PPARα activation is known to induce neuroprotection after focal ischemia [36, 78]. PPARα plays a very important regulatory role in response to injury or stress. As PPARα is known to be expressed when monocytes differentiate into macrophages, it influences postinjury inflammatory reactions [105]. Furthermore, agonist-induced activation of PPARα increases IκBα levels leading to an inhibition of NF-xB [106]. PPARα activation decreases the level of proatherosclerotic fibrinogen and C-reactive protein in experimental animals [107]. Fenofibrate, a potent exogenous agonist of PPARα, inhibits left ventricular hypertrophy by stimulating free fatty acid uptake and β-oxidation [63]. Fenofibrate pretreatment reduces the susceptibility of mice deficient in apolipoprotein-E, and decreases the infarct volume in wild type mice subjected to focal cerebral ischemia [78]. Poststroke neuroprotection induced by PPARα agonists will be mediated by both cerebral and vascular mechanisms. Fenofibrate treatment is known to decrease vascular endothelial dysfunction and improves endothelium-dependent vasodilatation in patients with hypertriglyceridemia [91]. Recent studies showed that a PPARα/γ dual agonist bezafibrate decreases anaerobic metabolism and thereby prevents death in gerbils subjected to global cerebral ischemia [108]. Fibrates are also reported to prevent secondary neuronal death by oxidative stress by enhancing the expression of antioxidant enzyme, Cu/Zn-SOD, and by decreasing vascular cell adhesion molecule 1 expression in CNS blood vessels, possibly by inhibiting the NF-xB pathway [98, 109]. The functional significance of PPARβ/δ in preventing CNS inflammation is not studied in detail. However, the PPARβ/δ agonists L-165041, and GW501516 were shown to significantly decrease focal ischemia-induced infarction and brain damage in adult rats [110]. In rodents, PPARβ/δ agonists were also demonstrated to prevent striatal dopamine loss after 1-methyl 4-phenyl 1,2,3,6-tetrahydrodipyridine administration [110]. PPARβ/δ agonist GW0742 was reported to inhibit lipopolysaccharide-induced TNFα secretion in cardiomyocytes [111].

16. CONCLUSIONS

Despite decades of research, no therapies that can prevent the secondary neuronal death and the ensuing neurological deficits after stroke are currently available. Many pathological mechanisms including inflammation, ionic imbalance, excitotoxicity, edema, oxidative stress, and ER stress synergistically promote the poststroke secondary neuronal death. Hence therapeutics that simultaneously targets several of these mechanisms with minimal side effects is extremely useful in stroke therapy. PPARγ agonists like rosiglitazone and pioglitazone are FDA approved and being prescribed to millions of type-2 diabetics all over the world. The benefit of these compounds seems to be their potential to influence multiple molecular mechanisms. For example, they are known to minimize the harmful events like inflammation and oxidative stress at the same time promote the antioxidant defence and protein chaperones. Hence PPARγ agonists might be an important class of drugs for use in stroke therapy. The benefits of PPARγ agonist treatment was also observed in other acute CNS injuries like SCIs as well as chronic neurodegenerative disorders like multiple sclerosis, Alzheimer’s disease, and Parkinson’s disease increasing the promise of these compounds as future neuroprotective therapies.

ACKNOWLEDGMENT

This paper is funded by NIH RO1 NS044173, NIH RO1 NS049448, and the American Heart Association Grant-in-Aid no. 0350164 N.

REFERENCES

[1] J. Berger and D. E. Moller, “The mechanisms of action of PPARs,” Annual Review of Medicine, vol. 53, pp. 409–435, 2002.
[2] S. Moreno, S. Farioli-Vecchioli, and M. P. Cerù, “Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS,” Neuroscience, vol. 123, no. 1, pp. 131–145, 2004.
[3] A. R. de Lera, W. Bourguet, L. Altucci, and H. Gronemeyer, “Design of selective nuclear receptor modulators: RAR and RXR as a case study,” Nature Reviews Drug Discovery, vol. 6, no. 10, pp. 811–820, 2007.
[4] D. J. Mangelsdorf, C. Thummel, M. Beato, et al., “The nuclear receptor superfamily: the second decade,” Cell, vol. 83, no. 6, pp. 835–839, 1995.

[5] R. Cunard, M. Ricote, D. DiCampli, et al., “Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors,” Journal of Immunology, vol. 168, no. 6, pp. 2795–2802, 2002.

[6] C. A. Argmann, T. A. Cock, and J. Auwerx, “Peroxisome proliferator-activated receptor γ: the more the merrier?” European Journal of Clinical Investigation, vol. 35, no. 2, pp. 82–92, 2005.

[7] K. Schoonjans, B. Staels, and J. Auwerx, “The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation,” Biochimica et Biophysica Acta, vol. 1302, no. 2, pp. 93–109, 1996.

[8] M. Lehrke and M. A. Lazar, “The many faces of PPARγ,” Cell, vol. 123, no. 6, pp. 993–999, 2005.

[9] B. Desvergne, L. Michalik, and W. Wahli, “Be fit or be sick: peroxisome proliferator-activated receptors are down the road,” Molecular Endocrinology, vol. 18, no. 6, pp. 1321–1334, 2004.

[10] L. C. Bell-Parikh, T. Ide, J. A. Lawson, P. McNamara, M. Reilly, and G. A. FitzGerald, “ Biosynthesis of 15-deoxy-D12,14-PGJ2 and the ligation of PPARγ,” Journal of Clinical Investigation, vol. 112, no. 6, pp. 945–955, 2003.

[11] O. Braissant, F. Foulelle, C. Scotto, M. Daucu, and W. Wahli, “Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-α-, β-, and γ- in the adult rat,” Endocrinology, vol. 137, no. 1, pp. 354–366, 1996.

[12] A. Bernardo, G. Levi, and L. Minghetti, “Role of the peroxisome proliferator-activated receptor-γ (PPAR-γ) and its natural ligand 15-deoxy-D12,14-prostaglandin J2 in the regulation of microglial functions,” European Journal of Neuroscience, vol. 12, no. 7, pp. 2215–2223, 2000.

[13] J. Sakamoto, H. Kimura, S. Moriyama, et al., “Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone,” Biochemical and Biophysical Research Communications, vol. 278, no. 3, pp. 704–711, 2000.

[14] D. J. Kudzma, “Effects of thiazolidinediones for early treatment of type 2 diabetes mellitus,” American Journal of Managed Care, vol. 8, supplement 16, pp. S472–S482, 2002.

[15] A. A. Bogan, F. E. Cohen, and T. S. Scanlan, “Natural ligands of nuclear receptors have conserved volumes,” Nature Structural Biology, vol. 5, no. 8, pp. 679–681, 1998.

[16] T. Shiraki, N. Kamiya, S. Shiki, T. S. Kodama, A. Kakizuka, and H. Jingami, “α,β-unsaturated ketone is a core moiety of natural ligands for covalent binding to peroxisome proliferator-activated receptor γ,” Journal of Biological Chemistry, vol. 280, no. 14, pp. 14145–14153, 2005.

[17] F. Chang, L. A. Jaber, H. D. Berlie, and M. B. O’Connell, “Evolution of peroxisome proliferator-activated receptor agonists,” Annals of Pharmacotherapy, vol. 41, no. 6, pp. 973–983, 2007.

[18] S. T. Olsen, P. Bruhn, and G. Obberg, “An ischemic penumbra as the cause of neurologic deficit in humans,” Journal of Cerebral Blood Flow & Metabolism, pp. S7–S8, 1985.

[19] P. J. Camarata, R. C. Heros, and R. E. Latchco, “Brain attack”: the rationale for treating stroke as a medical emergency,” Neurosurgery, vol. 34, no. 1, pp. 144–158, 1994.

[20] S. M. Lucas, N. J. Rothwell, and R. M. Gibson, “The role of inflammation in CNS disease and injury,” British Journal of Pharmacology, vol. 147, no. S1, pp. S232–S240, 2006.

[21] P. Lipton, “Ischemic cell death in brain neurons,” Physiological Reviews, vol. 79, no. 4, pp. 1431–1568, 1999.

[22] U. Dirnagl, C. Iadecola, and M. A. Moskowitz, “Pathobiology of ischaemic stroke: an integrated view,” Trends in Neurosciences, vol. 22, no. 9, pp. 391–397, 1999.

[23] D. Stanimirovic and K. Satoh, “Inflammatory mediators of cerebral endothelium: a role in ischemic brain inflammation,” Brain Pathology, vol. 10, no. 1, pp. 113–126, 2000.

[24] C. Iadecola and M. Alexander, “Cerebral ischemia and inflammation,” Current Opinion in Neurology, vol. 14, no. 1, pp. 89–94, 2001.

[25] I. Satriotomo, K. K. Bowen, and R. Vemuganti, “JAK2 and STAT3 activation contributes to neuronal damage following transient focal cerebral ischemia,” Journal of Neurochemistry, vol. 98, no. 5, pp. 1353–1368, 2006.

[26] V. L. Raghavendra Rao, K. K. Bowen, V. K. Dhodda, et al., “Gene expression analysis of spontaneously hypertensive rat cerebral cortex following transient focal cerebral ischemia,” Journal of Neurochemistry, vol. 83, no. 5, pp. 1072–1086, 2002.

[27] A. M. Planas, M. A. Soriano, M. Beruezo, et al., “Induction of Stat3, a signal transducer and transcription factor, in reactive microglia following transient focal cerebral ischemia,” European Journal of Neuroscience, vol. 8, no. 12, pp. 2612–2618, 1996.

[28] A. Lu, Y. Tang, R. Ran, J. F. Clark, B. J. Aronow, and F. R. Sharp, “Genomics of the periinfarction cortex after focal cerebral ischemia,” Journal of Cerebral Blood Flow and Metabolism, vol. 23, no. 7, pp. 786–810, 2003.

[29] C. Iadecola, C. A. Salkowski, F. Zhang, et al., “The transcription factor interferon regulatory factor 1 is expressed after cerebral ischemia and contributes to ischemic brain injury,” Journal of Experimental Medicine, vol. 189, no. 4, pp. 719–727, 1999.

[30] R. Kapadia, K. Tureyen, K. K. Bowen, H. Kalluri, P. F. Johnson, and R. Vemuganti, “Decreased brain damage and curtailed inflammation in transcription factor CCAAT/enhancer binding protein β knockout mice following transient focal cerebral ischemia,” Journal of Neurochemistry, vol. 98, no. 6, pp. 1718–1731, 2006.

[31] G. Z. Feurstein, X. K. Wang, and G. C. Barone, “Inflammatory mediators of ischemic injury: cytokine gene regulation in stroke,” in Cerebrovascular Disease: Pathophysiology, Diagnosis and Management, M. D. Ginsberg and J. Bogousslavsky, Eds., pp. 507–531, Blackwell, Malden, Mass, USA, 1998.

[32] K. Tureyen, R. Kapadia, K. K. Bowen, et al., “Peroxisome proliferator-activated receptor-γ agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents,” Journal of Neurochemistry, vol. 101, no. 1, pp. 41–56, 2007.

[33] A. Y. Shih, P. Li, and T. H. Murphy, “A small-molecule-inducible Nrf2-mediated antioxidant response provides effective prophylaxis against cerebral ischemia in vivo,” Journal of Neuroscience, vol. 25, no. 44, pp. 10321–10335, 2005.

[34] K. Tanaka, S. Nogawa, D. Ito, et al., “Activated phosphorylation of cyclic AMP response element binding protein is associated with preservation of striatal neurons after focal cerebral ischemia in the rat,” Neuroscience, vol. 100, no. 2, pp. 345–354, 2000.

[35] M. Bernaudin, A.-S. Nedelec, D. Divoux, E. T. MacKenzie, E. Petit, and P. Schumann-Bard, “Normobaric hypoxia induces...
tolerance to focal permanent cerebral ischemia in association with an increased expression of hypoxia-inducible factor-1 and its target genes, erythropoietin and VEGF, in the adult mouse brain,” Journal of Cerebral Blood Flow and Metabolism, vol. 22, no. 4, pp. 393–403, 2002.

[36] M. Collino, M. Aragno, R. Mastrocola, et al., “Oxidative stress and inflammatory response evoked by transient cerebral ischemia/reperfusion: effects of the PPAR-α agonist WY14643,” Free Radical Biology and Medicine, vol. 41, no. 4, pp. 579–589, 2006.

[37] N. S. Wayman, Y. Hattori, M. C. Mcdonald, et al., “Ligands of the peroxisome proliferator-activated receptors (PPAR-γ and PPAR-α) reduce myocardial infarct size,” The FASEB Journal, vol. 16, no. 9, pp. 1027–1040, 2002.

[38] H.-R. Liu, L. Tao, E. Gao, et al., “Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion,” Cardiovascular Research, vol. 62, no. 1, pp. 135–144, 2004.

[39] P. Aoun, D. G. Watson, and J. W. Simpkins, “Neuroprotective effects of PPARγ agonists against oxidative insults in HT-22 cells,” European Journal of Pharmacology, vol. 472, no. 1-2, pp. 65–71, 2003.

[40] G. E. Landreth and M. T. Heneka, “Anti-inflammatory actions of peroxisome proliferator-activated receptor γ agonists in Alzheimer’s disease,” Neurobiology of Aging, vol. 22, no. 6, pp. 937–944, 2001.

[41] M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, “The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation,” Nature, vol. 391, no. 6662, pp. 79–82, 1998.

[42] C. Jiang, A. T. Ting, and B. Seed, “PPAR-γ agonists inhibit production of monocyte inflammatory cytokines,” Nature, vol. 391, no. 6662, pp. 82–86, 1998.

[43] J. L. Mehta, B. Hu, I. Chen, and D. Li, “Pioglitazone inhibits LOX-1 expression in human coronary artery endothelial cells by reducing intracellular superoxide radical generation,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 12, pp. 2203–2208, 2003.

[44] K. Chen, D. Li, X. Zhang, P. L. Hermonat, and J. L. Mehta, “Anoxia-reoxygenation stimulates collagen type-I and MMP-1 expression in cardiac fibroblasts: modulation by the PPAR-γ ligand pioglitazone,” Journal of Cardiovascular Pharmacology, vol. 44, no. 6, pp. 682–687, 2004.

[45] H. Ito, A. Nakano, M. Kinoshita, and A. Matsumori, “Pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, attenuates myocardial ischemia/reperfusion injury in a rat model,” Laboratory Investigation, vol. 83, no. 12, pp. 1715–1721, 2003.

[46] W.-W. Yan, Z.-G. Zhou, Y.-D. Chen, and H.-K. Gao, “Role of COX-2 in microcirculatory disturbance in experimental pancreatitis,” World Journal of Gastroenterology, vol. 10, no. 14, pp. 2095–2098, 2004.

[47] L. Michalik and W. Wahl, “Involvement of PPAR nuclear receptors in tissue injury and wound repair,” Journal of Clinical Investigation, vol. 116, no. 3, pp. 598–606, 2006.

[48] N. Sattar, D. W. McCarey, H. Capell, and I. B. McInnes, “Explaining how ‘high-grade’ systemic inflammation accelerates vascular risk in rheumatoid arthritis,” Circulation, vol. 108, no. 24, pp. 2957–2963, 2003.

[49] S. Cuzzocrea, B. Pisano, L. Dugo, et al., “Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-γ, reduces acute pancreatitis induced by cerulein,” Intensive Care Medicine, vol. 30, no. 5, pp. 951–956, 2004.

[50] N. Marx, J. Frohlich, L. Siamb, et al., “Antidiabetic PPARy-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 2, pp. 283–288, 2003.

[51] S. Cuzzocrea, “Peroxisome proliferator-activated receptors y ligands and ischemia and reperfusion injury,” Vascular Pharmacology, vol. 41, no. 6, pp. 187–195, 2004.

[52] A. Rossi, P. Kapahi, G. Natoli, et al., “Anti-inflammatory cyclopenteno prostaglandins are direct inhibitors of iKB kinase,” Nature, vol. 403, no. 6765, pp. 103–108, 2000.

[53] A. Sivarajah, I. A. Patel, et al., “Agonists of peroxisome-proliferator activated receptor-γ reduce renal ischemia/reperfusion injury,” American Journal of Nephrology, vol. 23, no. 4, pp. 267–276, 2003.

[54] S. L. Tilley, T. M. Coffman, and B. H. Koller, “Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes,” Journal of Clinical Investigation, vol. 108, no. 1, pp. 15–23, 2001.

[55] D. S. Straus, G. Pascual, M. Li, et al., “15-Deoxy-D12,14-prostaglandin J1, inhibits multiple steps in the NF-kB signaling pathway,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 9, pp. 4844–4849, 2000.

[56] P. Delerive, J.-C. Fruchart, and B. Staels, “Peroxisome proliferator-activated receptors in inflammation control,” Journal of Endocrinology, vol. 169, no. 3, pp. 453–459, 2001.

[57] M. D. Linnik, R. H. Zobrist, M. D. Hatfield, and W. J. Koroshetz, “Evidence supporting a role for programmed cell death in focal cerebral ischemia in rats,” Stroke, vol. 24, no. 12, pp. 2002–2009, 1993.

[58] J. Yrjänheikki, T. Tikka, R. Keinänen, G. Goldsteins, P. H. Chan, and J. Koistinaho, “A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 23, pp. 13496–13500, 1999.

[59] J. Jiang, W. Wang, Y. J. Sun, M. Hu, F. Li, and D. Y. Zhu, “Neuroprotective effect of curcumin on focal cerebral ischemic rats by preventing blood-brain barrier damage,” European Journal of Pharmacology, vol. 561, no. 1–3, pp. 54–62, 2007.

[60] M. Khan, C. Elango, M. A. Ansari, I. Singh, and A. K. Singh, “Cafliefic acid phenethyl ester reduces neurovascular inflammation and protects rat brain following transient focal cerebral ischemia,” Journal of Neurochemistry, vol. 102, no. 2, pp. 365–377, 2007.

[61] J. Shen, H. Zhang, H. Lin, H. Su, D. Xing, and L. Du, “Brazilien protects the brain against focal cerebral ischemia reperfusion injury correlating to inflammatory response suppression,” European Journal of Pharmacology, vol. 558, no. 1–3, pp. 88–95, 2007.

[62] N. Kagansky, S. Levy, and H. Knobler, “The role of hyperglycemia in acute stroke,” Archives of Neurology, vol. 58, no. 8, pp. 1209–1212, 2001.

[63] T. Ogata, T. Miyauchi, S. Sakai, Y. Irukayama-Tomobe, K. Goto, and I. Yamaguchi, “Stimulation of peroxisome-proliferator-activated receptor α (PPARα) attenuates cardiac fibrosis and endothelin-1 production in pressure-overloaded rat hearts,” Clinical Science, vol. 103, supplement 48, pp. 284S–288S, 2002.

[64] N. A. Victor, E. W. Wanderi, J. Gamboa, et al., “Altered PPARy expression and activation after transient focal
ischemia in rats,” European Journal of Neuroscience, vol. 24, no. 6, pp. 1653–1663, 2006.

[65] E. Y. Park, I. J. Cho, and S. G. Kim, “Transactivation of the PPAR-responsive enhancer module in chemopreventive glutathione S-transferase gene by the peroxisome proliferator-activated receptor-γ and retinoid X receptor heterodimer,” Cancer Research, vol. 64, no. 10, pp. 3701–3713, 2004.

[66] S. Sundararajana, J. L. Gambord, N. A. Victor, E. W. Wunder, W. D. Lust, and G. E. Landreth, “Peroxisome proliferator-activated receptor-γ ligands reduce inflammation and infarct size in transient focal ischemia,” Neuroscience, vol. 130, no. 3, pp. 685–696, 2005.

[67] Y. Zhao, A. Patzer, P. Gohlke, T. Herdegen, and J. Culman, “The intracerebral application of the PPARγ-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain,” European Journal of Neuroscience, vol. 22, no. 1, pp. 278–282, 2005.

[68] Y. Luo, W. Yin, A. P. Signore, et al., “Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone,” Journal of Neurochemistry, vol. 97, no. 2, pp. 435–448, 2006.

[69] M. Allahatavokoli, A. Shahbanazadeh, A. Roohbakhsh, and A. Pourshahzadi, “Combination therapy of rosiglitazone, a peroxisome proliferator-activated receptor-γ ligand, and NMDA receptor antagonist (MK-801) on experimental embolic stroke in rats,” Basic and Clinical Pharmacology and Toxicology, vol. 101, no. 5, pp. 309–314, 2007.

[70] K. Chu, S.-T. Lee, J.-S. Koo, et al., “Peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, promotes angiogenesis after focal cerebral ischemia,” Brain Research, vol. 1093, no. 1, pp. 208–218, 2006.

[71] T. Shimazu, I. Inoue, N. Araki, et al., “A peroxisome proliferator-activated receptor-γ agonist reduces infarct size in transient but not in permanent ischemia,” Stroke, vol. 36, no. 2, pp. 353–359, 2005.

[72] G. Pascual, A. L. Fong, S. Ogawa, et al., “A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ,” Nature, vol. 437, no. 7039, pp. 759–763, 2005.

[73] Y. Takata, Y. Kitami, Z.-H. Yang, M. Nakamura, T. Okura, and K. Hiwada, “Vascular inflammation is negatively autoregulated by interaction between CCAAT/enhancer-binding protein-β and peroxisome proliferator-activated receptor-γ,” Circulation Research, vol. 91, no. 5, pp. 427–433, 2002.

[74] D. L. Feinstein, A. Spagnolo, C. Akar, et al., “Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key?” Biochemical Pharmacology, vol. 70, no. 2, pp. 177–188, 2005.

[75] C. Dello Russo, V. Gavrilyuk, G. Weinberg, et al., “Peroxisome proliferator-activated receptor γ thiazolidinedione agonists increase glucose metabolism in astrocytes,” Journal of Biological Chemistry, vol. 278, no. 8, pp. 5828–5836, 2003.

[76] P. W. Young, D. R. Buckle, B. C. C. Cantello, et al., “Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radiolabeled ligand for peroxisomal proliferator-activated receptor γ,” Journal of Pharmacology and Experimental Therapeutics, vol. 284, no. 2, pp. 751–759, 1998.

[77] S.-W. Park, J.-H. Yi, G. Miranpuri, et al., “Thiazolidinedione class of peroxisome proliferator-activated receptor γ agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats,” Journal of Pharmacology and Experimental Therapeutics, vol. 320, no. 3, pp. 1002–1012, 2007.

[78] D. Deplanque, P. Gelé, O. Petrault, et al., “Peroxisome proliferator-activated receptor-α activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment,” Journal of Neuroscience, vol. 23, no. 15, pp. 6264–6271, 2003.

[79] R. Bordet, T. Ouk, O. Petrault, et al., “PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases,” Biochemical Society Transactions, vol. 34, no. 6, pp. 1341–1346, 2006.

[80] M. Collino, M. Aragno, R. Mastrocola, et al., “Modulation of the oxidative stress and inflammatory response by PPAR-γ agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion,” European Journal of Pharmacology, vol. 530, no. 1-2, pp. 70–80, 2006.

[81] J. Hwang, D. J. Kleinhenz, B. Lassègue, K. K. Griendling, S. Dikalov, and C. M. Hart, “Peroxisome proliferator-activated receptor-γ ligands regulate endothelial membrane superoxide production,” American Journal of Physiology, vol. 288, no. 4, pp. C899–C905, 2005.

[82] E. Geremia, D. Baratta, S. Zafarana, et al., “Antioxidant enzymatic systems in neuronal and glial cell-enriched fractions of rat brain during aging,” Neurochemical Research, vol. 15, no. 7, pp. 719–723, 1990.

[83] S. Moreno, E. Mugnaini, and M. P. Ceru, “Immunochemical localization of catalase in the central nervous system of the rat,” Journal of Histochemistry and Cytochemistry, vol. 43, no. 12, pp. 1253–1267, 1995.

[84] G. D. Gurnun, F. E. Domann, S. A. Moore, and M. E. C. Robbins, “Identification of a functional peroxisome proliferator-activated receptor response element in the rat catalase promoter,” Molecular Endocrinology, vol. 16, no. 12, pp. 2793–2801, 2002.

[85] B. Herrera, A. M. Álvarez, A. Sánchez, et al., “Reactive oxygen species (ROS) mediates the mitochondrial-dependent apoptosis induced by transforming growth factor β in fetal hepatocytes,” The FASEB Journal, vol. 15, no. 3, pp. 741–751, 2001.

[86] M. A. Perez-Pinzon, K. R. Dave, and A. P. Raval, “Role of reactive oxygen species and protein kinase C in ischemic tolerance in the brain,” Antioxidants and Redox Signaling, vol. 7, no. 9-10, pp. 1150–1157, 2005.

[87] T.-N. Lin, W.-M. Cheung, J.-S. Wu, et al., “15d-prostaglandin J2 protects brain from ischemia-reperfusion injury,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 3, pp. 481–487, 2006.

[88] D. Sulejczak, C. Czarkowska-Bauch, M. Macias, and M. Skup, “Bel-2 and Bax proteins are increased in neocortical but not in thalamic apoptosis following devascularization lesion of the cerebral cortex in the rat: an immunohistochemical study,” Brain Research, vol. 1006, no. 2, pp. 133–149, 2004.

[89] B. Charbonnel, J. Dormandy, E. Erdmann, M. Massi-Benedetti, and A. Skene, “The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5,238 patients,” Diabetes Care, vol. 27, no. 7, pp. 1647–1653, 2004.

[90] J. A. Dormandy, B. Charbonnel, D. J. Eckland, et al., “Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitazone clinical trial in macrovascular events): a randomised controlled trial,” Lancet, vol. 366, no. 9493, pp. 1279–1289, 2005.
[91] Y. Huang, G. Dai, Z. Feng, et al., “Effect of micronized fenofibrate on vascular endothelial function in patients with hypertriglyceridemia,” *Chinese Medical Journal*, vol. 116, no. 11, pp. 1767–1769, 2003.

[92] H. Yki-Järvinen, “The PROactive study: some answers, many questions,” *Lancet*, vol. 366, no. 9493, pp. 1241–1242, 2005.

[93] J. Lee and M. Reding, “Effects of thiazolidinediones on stroke recovery: a case-matched controlled study,” *Neurochemical Research*, vol. 32, no. 4-5, pp. 635–638, 2007.

[94] A. Diab, C. Deng, J. D. Smith, et al., “Peroxisome proliferator-activated receptor-γ agonist 15-deoxy-A[12,14]-prostaglandin J2 ameliorates experimental autoimmune encephalomyelitis,” *Journal of Immunology*, vol. 168, no. 5, pp. 2508–2515, 2002.

[95] M. Kiaei, K. Kipiani, J. Chen, N. Y. Calingasan, and M. F. Beal, “Peroxisome proliferator-activated receptor-γ agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis,” *Experimental Neurology*, vol. 191, no. 2, pp. 331–336, 2005.

[96] R. E. Mrak and G. E. Landreth, “PPARγ, neuroinflammation, and disease,” *Journal of Neuroinflammation*, vol. 1, pp. 1–3, 2004.

[97] J. Culman, Y. Zhao, P. Gohlke, and T. Herdegen, “PPAR-γ: therapeutic target for ischemic stroke,” *Trends in Pharmacological Sciences*, vol. 28, no. 5, pp. 244–249, 2007.

[98] D. L. Feinstein, “Therapeutic potential of peroxisome proliferator-activated receptor agonists for neurological disease,” *Diabetes Technology and Therapeutics*, vol. 5, no. 1, pp. 67–73, 2003.

[99] T. Breidert, J. Callebert, M. T. Heneka, G. Landreth, J. M. Launay, and E. C. Hirsch, “Protective action of the peroxisome proliferator-activated receptor-γ agonist pioglitazone in a mouse model of Parkinson’s disease,” *Journal of Neurochemistry*, vol. 82, no. 3, pp. 615–624, 2002.

[100] L. Steinman, R. Martin, C. Bernard, P. Conlon, and J. R. Oksenberg, “Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy,” *Annual Review of Neuroscience*, vol. 25, pp. 491–505, 2002.

[101] B. Schütz, J. Reimann, L. Dumitrescu-Ozimek, et al., “The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice,” *Journal of Neuroscience*, vol. 25, no. 34, pp. 7803–7812, 2005.

[102] P. N. Pompl, L. Ho, M. Bianchi, T. McManus, W. Qin, and G. M. Pasinetti, “A therapeutic role for cyclooxygenase-2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis,” *The FASEB Journal*, vol. 17, no. 6, pp. 725–727, 2003.

[103] D. M. McTigue, R. Tripathi, P. Wei, and A. T. Lash, “The PPAR y agonist Pioglitazone improves anatomical and locomotor recovery after rodent spinal cord injury,” *Experimental Neurology*, vol. 205, no. 2, pp. 396–406, 2007.

[104] E. J. Park, S. Y. Park, E.-H. Joe, and I. Jou, “15d-PGJ2 and rosiglitazone suppress Janus kinase-STAT inflammatory signaling through induction of suppressor of cytokine signaling 1 (SOCS1) and SOCS3 in glia,” *Journal of Biological Chemistry*, vol. 278, no. 17, pp. 14747–14752, 2003.

[105] B. P. Neve, D. Corseaux, G. Chinetti, et al., “PPARα agonists inhibit tissue factor expression in human monocytes and macrophages,” *Circulation*, vol. 103, no. 2, pp. 207–212, 2001.

[106] N. F. L. Spencer, M. E. Poynter, S.-Y. Im, and R. A. Daynes, “Constitutive activation of NF-κB in an animal model of aging,” *International Immunology*, vol. 9, no. 10, pp. 1581–1588, 1997.

[107] B. Kieć-Wilk, A. Dembińska-Kieć, A. Olszanecka, M. Bodziocz, and K. Kawecka-Jaszcz, “The selected pathophysiological aspects of PPARs activation,” *Journal of Physiology and Pharmacology*, vol. 56, no. 2, pp. 149–162, 2005.

[108] B. S. Aspey, S. Ehteshami, C. M. Hurst, S. Pereira, and M. J. G. Harrison, “Effect of bezafibrate on the sequelae of acute experimental focal cerebral ischaemia,” *Journal of Neurology Neurosurgery and Psychiatry*, vol. 52, no. 12, pp. 1432–1434, 1989.

[109] F. O’Rourke, N. Dean, N. Akhtar, and A. Shuaib, “Current and future concepts in stroke prevention,” *Canadian Medical Association Journal*, vol. 170, no. 7, pp. 1123–1133, 2004.

[110] A. Iwashita, Y. Muramatsu, T. Yamazaki, et al., “Neuroprotective efficacy of the peroxisome proliferator-activated receptor δ-selective agonists in vitro and in vivo,” *Journal of Pharmacology and Experimental Therapeutics*, vol. 320, no. 3, pp. 1087–1096, 2007.

[111] G. Ding, L. Cheng, Q. Qin, S. Frontin, and Q. Yang, “PPARδ modulates lipopolysaccharide-induced TNFα inflammation signaling in cultured cardiomyocytes,” *Journal of Molecular and Cellular Cardiology*, vol. 40, no. 6, pp. 821–828, 2006.